![Marja-Riita Taskinen](https://www.triglycerideforum.org/wp-content/uploads/2020/12/Taskinen-MR_cropped.jpg)
![Marja-Riita Taskinen](https://www.triglycerideforum.org/wp-content/uploads/2020/12/Taskinen-MR_cropped.jpg)
Newly published data on the postprandial kinetics of apoB48 and B100 in chylomicrons, VLDL1, VLDL2, IDL and LDL, in people heterozygous for a loss-of-function (LOF) mutation in the APOC3 gene, indicate the potential benefits of apoCIII lowering for cardiovascular disease (CVD) prevention.1 First author of the paper in JCI Insight, Professor Marja-Riitta Taskinen (Faculty of Medicine, University of Helsinki, Finland), describes the new findings in relation to previous research and the role of apoCIII as a treatment target.